Worldwide Analysis On Unfractionated Heparin Market Size, Share And Trends By 2020 – 2026
SEATTLE, March 31, 2021, (PHARMIWEB) — Global Unfractionated Heparin Market
Unfractionated heparin (UFH) is a natural agent that is widely used to prevent clot formation in blood vessels. Unfractionated heparin is a fast-acting blood thinner that works with antithrombin, which is a natural protein present in the body, to inhibit clot formation. UFH is administered to patient intravenously into an arm vein or as a subcutaneous injection under the skin. UFH can also be administrated orally. However, oral absorption of unfractionated heparin is poor, owing to their size and anionic structure. UFH is not absorbed properly from the gastrointestinal tract when taken orally.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-pdf/1672
Unfractionated heparin is majorly used in deep venous thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE) in patients with increased postoperative complications. Unfractionated heparin is the preferred treatment for patients, who are at a high risk of bleeding complications, owing to its short-term activity, reversibility, and reversible anticoagulant effect. In addition, UTH offers various advantages over other types of heparin, on account of its ability to rapidly enter into the blood stream and kidneys for extraction. UTH is a preferred anticoagulant option for pregnant women, as it does not cross the placenta, and is thus considered safe for the fetus.
Global Unfractionated Heparin Market Dynamics
Growth of the global unfractionated heparin market is accredited to the increasing incidence of thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism, and others. According to the findings of the Centers for Disease Control and Prevention (CDC), published in February 2018, around 900,000 people are affected (1 to 2 per 1,000) each year in the U.S., due to the deep venous thromboembolism and Pulmonary Embolism (DVT/PE). As per the data published in the Circulation Research Journal, a journal of the American Heart Association, in 2016, the incidence of venous thromboembolism (VTE) increases with growing age. The source further reported that up to 143 per 100000 individuals aged 40 years to 49 years, 200 per 100 000 among ages 50 to 59 years, 391 per 100000 among ages 60 to 69 years, 727 per 100000 among ages 70 to 79 years, and 1134 per 100000 among ages ≥80 years. Additionally, the low awareness regarding the pulmonary embolism and deep-vein thrombosis showing the negligence towards the early diagnosis of these condition. Moreover, healthcare regularity organizations are engaged in increasing the awareness for the same, which will expected to drive the unfractionated heparin market in near future.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://bit.ly/2O6IgWW
However, adverse effects of unfractionated heparin during treatment, poses as a major restraint for growth of the unfractionated heparin market. Heparin-induced thrombocytopenia (HIT), an adverse reaction occurring during treatment with heparin, is associated with inconsistent increase in the clotting causing further complications. For instance, according to the data published in American Society of Hematology in 2017, Heparin-induced thrombocytopenia (HIT) is heparin’s most clinically relevant non-hemorrhagic complication. Furthermore, adults receiving heparin formulation for medical or general surgical indications are at higher risk for HIT than pediatric or obstetric patients.
Moreover, cost-effectiveness of low-molecular weight heparin over the unfractionated heparin in venous thromboembolism (VTE) prevention in critical illness, limits the adoption of unfractionated heparin. According to the data published in the Journal of American Medical Association (AMA), in November 2014, hospital costs per patient using low-molecular weight heparin were a median of US$ 39,508 compared with US$ 40,805 on unfractionated heparin. Moreover, low-molecular weight heparin was found to be more effective and least costly in treating VTE.
Global Unfractionated Heparin Market – Regional Analysis
North America holds a leading position in the global unfractionated heparin market, owing to increasing prevalence of deep venous thromboembolism and Pulmonary Embolism in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), February 2018 data findings, around 60,000 to 100,000 people are estimated to die due to DVT/PE, in the U.S. Moreover, 10% to 30% of people die within one month from diagnosis. Additionally, according to the same source, around 5% to 8% of the U.S. population has one of several genetic risk factors, such as inherited thrombophilias, which increases the risk for thrombosis.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/unfractionated-heparin-market-1672
Global Unfractionated Heparin Market Competitive Landscape
Some of the key players operating in the global unfractionated heparin market are B. Braun Melsungen AG, Pfizer, Inc., Baxter International Inc., Siemens Ag, Sagent Pharmaceuticals, Inc., and LEO Pharma A/S.
Research advancements in unfractionated heparin are expected to create new application areas in the treatment of Chronic Obstructive Pulmonary Disease (COPD). A pilot study performed at the University of Portsmouth in December 2017, evaluated that the use of inhaled nebulized unfractionated heparin is an effective treatment for moderate-to-severe COPD. Unfractionated heparin is claimed to significantly improve lung function and reduce labored breathing.
Global Unfractionated Heparin Market Taxonomy
- Deep Vein Thrombosis
- Pulmonary Embolism
- Arterial Embolism
By End User,
- Ambulatory Surgical Centers
- Academic and Research Organizations
- North America
- Latin America
- Asia Pacific
- Middle East
Table of Content
Global Unfractionated Heparin Market Research Report
Section 1: Global Unfractionated Heparin Industry Overview
Section 2: Global Economic Impact on Unfractionated Heparin Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Unfractionated Heparin Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Unfractionated Heparin Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire